Results 231 to 240 of about 400,631 (298)

Mitochondrial Protection and Neural Repair via ROS‐Responsive Biomimetic Nanoparticles in Intracerebral Hemorrhage

open access: yesAdvanced Science, EarlyView.
A ROS‐responsive biomimetic nanoparticle platform co‐delivers DIDS and Mdivi‐1 to protect mitochondria and promote neural repair after intracerebral hemorrhage. By targeting LPAR1/VDAC1‐related mitochondrial dysfunction, the nanotherapy reduces oxidative injury, neuronal apoptosis, and blood‐brain barrier disruption, improving neurological recovery and
Ling Gao   +7 more
wiley   +1 more source

Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment. [PDF]

open access: yesMolecules
Aksoy OA   +9 more
europepmc   +1 more source

Decoding Biomolecular Phase Separation: From Physiological Roles to Pathological Mechanisms and Therapeutic Biomaterials Design

open access: yesAdvanced Science, EarlyView.
This review systematically elaborates on the mechanisms underlying physiological regulation and pathological dysregulation of biomolecular phase separation. It also summarizes advances in phase‑separation‑targeted therapeutic strategies and the design of functional biomaterials inspired by this process.
Jiawei Zhu   +5 more
wiley   +1 more source

Digoxin Alleviates Osteoarthritis by Inhibiting Macrophage Extracellular Trap Formation via Disruption of the LSP1‐SOD1 Interaction

open access: yesAdvanced Science, EarlyView.
Synovial macrophages in osteoarthritis upregulate LSP1, which directly binds and inhibits SOD1, triggering a redox imbalance that activates both NOX and mitochondrial ROS pathways. This cascade drives the release of macrophage extracellular traps (METs), causing chondrocyte damage and disease progression.
Yankai Pan   +9 more
wiley   +1 more source

Pharmacokinetics

Biochemical Pharmacology, 2014
Pharmacokinetics (PK) is the study of the time course of the absorption, distribution, metabolism and excretion (ADME) of a drug, compound or new chemical entity (NCE) after its administration to the body. Following a brief introduction as to why knowledge of the PK properties of an NCE is critical to its selection as a lead candidate in a drug ...
Jianghong, Fan, Inés A M, de Lannoy
openaire   +2 more sources

Lumping in Pharmacokinetics

Journal of Pharmacokinetics and Pharmacodynamics, 2005
Pharmacokinetic (PK) models simplify biological complexity by dividing the body into interconnected compartments. The time course of the chemical's amount (or concentration) in each compartment is then expressed as a system of ordinary differential equations.
Brochot, Céline   +2 more
openaire   +4 more sources

Insulin Pharmacokinetics

Diabetes Care, 1984
Where adjustments of diet, physical activity, and dosage of insulin are well known to diabetologists and diabetic patients, present-day knowledge of factors of importance to the pharmacokinetics of insulin is frequently ignored. The pharmacokinetics of insulin comprise the absorption process, the distribution including binding to circulating insulin ...
Binder, C   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy